Open AccessPharmacological Profile of the 5‐HT 2C Receptor Agonist WAY‐163909; Therapeutic Potential in Multiple Indications
Author(s) -
Dunlop John,
Marquis Karen L.,
Lim HK,
Leung Louis,
Kao John,
Cheesman Cynthia,
RosenzweigLipson Sharon
Publication year - 2006
Publication title -
cns drug reviews
Language(s) - English
Resource type - Journals
eISSN - 1527-3458
pISSN - 1080-563X
DOI - 10.1111/j.1527-3458.2006.00167.x
Subject(s) - agonist , schizophrenia (object oriented programming) , migraine , depression (economics) , partial agonist , pharmacology , 5 ht2c receptor , receptor , medicine , neuroscience , psychology , 5 ht receptor , psychiatry , serotonin , economics , macroeconomics
The 5‐HT 2C receptor subtype has been implicated in a wide variety of conditions including obesity, anxiety, depression, obsessive compulsive disorder, schizophrenia, migraine and erectile dysfunction and as a consequence has received considerable attention as a target for drug discovery. Here we review the pharmacological, pharmacokinetic and toxicological profile of WAY‐163909 {(7b R ,10a R )‐1,2,3,4,8,9,10,10a‐octahydro‐7b H ‐cyclopenta‐[b][1,4]diazepino[6,7,1hi]indole}, a novel 5‐HT 2C receptor selective agonist. Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY‐163909 was found to have robust dose‐dependent effects in animal models of obesity, psychotic‐like behavior or depression.